The biomedical engineering industry in Benelux thrives on innovation, combining engineering principles with medical sciences to improve healthcare solutions. Companies range from startups developing cutting-edge medical devices to established firms optimizing imaging technologies and therapeutic solutions. This sector not only drives advancements in patient care but also significantly contributes to the local economies, with a growing focus on integrative health technologies that enhance healthcare delivery. The industry is on a path of transformation, fueled by research collaborations and investments that prioritize sustainability, precision medicine, and personalized treatment approaches, aligning with global health trends and evolving patient needs.


The list of investors showcases a mix of corporate and venture capital firms, with headquarters spanning Amsterdam, Luxembourg, and Brussels. These firms vary in size, from small teams to large entities, and were established between 1980 and 2014, reflecting a blend of fresh perspectives and seasoned experience. In 2024, these investors collectively made over 300 investments, indicating a robust and growing interest in the biomedical engineering sector, supporting both innovative startups and established companies alike, demonstrating confidence in the future of healthcare technology.


Top 16 Biomedical Engineering Investors in Benelux


1. European Innovation Council (EIC)


The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, the EIC offers various funding programs, including the EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale their technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation in multiple sectors. Notably, the EIC has been involved in significant transactions within the biomedical engineering space, such as providing grants to CorTec and Lattice Medical, the latter of which raised over $7.8 million in a Series A round. These transactions highlight the EIC's commitment to supporting innovative companies in the biomedical field, making it a relevant player in this investment category.


2. European Investment Bank (EIB)


The European Investment Bank (EIB) is a public entity based in Luxembourg, founded in 1958, that provides financial services such as loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. In 2024, the EIB was involved in 99 investments, demonstrating its active role in financing diverse initiatives. Notably, the EIB has participated in significant transactions in the biomedical engineering field, including a €75 million funding agreement with CureVac for its infectious disease vaccine programs, which highlights its commitment to supporting healthcare innovations. Other relevant transactions include debt financing for companies like CARMAT and Xeltis, which are engaged in advanced medical technologies. These activities underscore the EIB's role as a key player in financing projects that promote growth and job creation in the biomedical sector.


3. Life Sciences Partners (LSP)

  • Website: lspvc.com
  • Type: Venture Capital
  • Headquarters: Amsterdam, North Holland, Netherlands
  • Founded year: 1987
  • Headcount: 11-50
  • Number of deals in 2024: 15
  • LinkedIn: lsp-bioventures

Life Sciences Partners (LSP) is an investment firm based in Amsterdam, Netherlands, founded in 1987. The firm specializes in private equity investments within the healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on drug development and medical technology, aiming to foster advancements in healthcare that address unmet medical needs. Notably, LSP has been involved in several funding rounds for Xeltis, a company dedicated to developing polymer-based heart valve replacements. In 2023, Xeltis raised over $13 million in a Series D round, and earlier in 2017, they participated in a $52 million Series C round to support clinical activities and product development for heart valve programs. These transactions highlight LSP's commitment to investing in biomedical engineering innovations.


4. Forbion

  • Website: forbion.com
  • Type: Venture Capital
  • Headquarters: Naarden, North Holland, Netherlands
  • Founded year: 2006
  • Headcount: 11-50
  • Number of deals in 2024: 23
  • LinkedIn: forbion-capital-partners

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, Netherlands. The firm specializes in the life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to develop innovative therapies and technologies aimed at improving patient outcomes. Notable transactions include investments in Acorda Therapeutics, which raised $55.3 million in Series B funding, and multiple rounds of funding for argenx, totaling over $60 million across Series A and B rounds. Additionally, Forbion invested $60 million in Bluebird Bio during their Series D round, further demonstrating their active role in supporting advancements in biomedical engineering and related fields.


5. Gilde Healthcare


Gilde Healthcare is a venture capital firm based in Utrecht, Netherlands, specializing in healthcare investments. Founded in 1982, the firm manages over €2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare invests in innovative healthtech and therapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. Notably, Gilde has been involved in several key transactions in the biomedical engineering sector, including leading funding rounds for Ablative Solutions, which focuses on renal denervation technology, and Inari Medical, which is developing innovative solutions for vascular diseases. These investments highlight Gilde's commitment to supporting advancements in medical technology and healthcare innovation.


6. M Ventures

  • Website: m-ventures.com
  • Type: Venture Capital
  • Headquarters: Amsterdam, North Holland, Netherlands
  • Founded year: 2009
  • Headcount: 11-50
  • Number of deals in 2024: 18
  • LinkedIn: merck-ventures

M Ventures is a venture capital fund based in Amsterdam, Netherlands, founded in 2009. The firm specializes in investing in transformative ideas within the biotechnology and technology sectors, with a strong focus on healthcare and life sciences. M Ventures provides funding and strategic guidance to startups, helping them achieve commercial success and drive innovation. Among their notable transactions, M Ventures led a $22 million Series A funding round for CellFE, a company developing new approaches to cell therapies using microfluidics, which aims to enhance the accessibility and affordability of these therapies. Additionally, they participated in a seed funding round for Astraveus, a France-based company, indicating their active engagement in the biotechnology sector. These investments highlight M Ventures' commitment to supporting advancements in biomedical engineering and related fields.


7. Gimv

  • Website: gimv.com
  • Type: Venture Capital
  • Headquarters: Antwerp, Flanders, Belgium
  • Founded year: 1980
  • Headcount: 51-200
  • Number of deals in 2024: 8
  • LinkedIn: gimv

Gimv is a venture capital investment firm based in Antwerp, Flanders, Belgium, founded in 1980. The firm partners with innovative companies across various sectors, including Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. Gimv provides investment management and strategic support to help businesses grow sustainably. Notably, Gimv has participated in several significant transactions in the biomedical engineering space, particularly with JenaValve Technology, which focuses on developing transcatheter aortic valve implantation systems. Gimv's involvement in multiple funding rounds for JenaValve, including a $100 million Series C financing and earlier equity financing rounds, highlights their active role in supporting advancements in biomedical technologies. Their clientele primarily consists of entrepreneurial companies seeking capital and expertise to navigate market challenges, further emphasizing their relevance in the biomedical engineering sector.


8. Brabantse Ontwikkelings Maatschappij (BOM)


The Brabantse Ontwikkelings Maatschappij (BOM) is a venture capital development agency based in Tilburg, North Brabant, Netherlands, founded in 1983. BOM supports startups and scale-ups in the Brabant region through various programs aimed at enhancing business growth, including readiness programs for venture capital and innovation in sustainable food and energy sectors. In recent years, BOM has made significant investments in the biomedical engineering sector, including participation in funding rounds for companies like STENTiT, which raised €1.8 million to develop regenerative stents, and Vivolta, which secured €7 million to enhance its MediSpinTM platform. These transactions highlight BOM's active role in the biomedical field, alongside their broader investment strategy.


9. Noshaq

  • Website: noshaq.be
  • Type: Venture Capital
  • Headquarters: Belgium
  • Founded year: 1985
  • Headcount: 11-50
  • Number of deals in 2024: 11
  • LinkedIn: noshaq-be

Noshaq is a venture capital investment fund based in Belgium, established in 1985. The firm specializes in providing financial solutions and strategic support to small and medium-sized enterprises (SMEs) in the province of Liege, with a particular focus on sectors such as biotech and sustainable development. Noshaq aims to foster growth and innovation by actively engaging with its clients and offering tailored financial assistance. Notably, Noshaq has participated in significant funding rounds for companies in the biomedical engineering space, including Intressa Vascular, a clinical-stage MedTech company that raised €18 million to support its clinical development and product registration activities. Additionally, Noshaq has been involved in multiple funding rounds for Miracor Medical, which focuses on innovative medical technologies, raising substantial amounts in Series D and E funding rounds. These transactions highlight Noshaq's commitment to advancing the biomedical engineering sector through strategic investments.


10. BGV (BioGeneration Ventures)


BGV (BioGeneration Ventures) is a venture capital firm founded in 2006, located in Naarden, North Holland, Netherlands. The firm specializes in seed investments in innovative early-stage biotech companies, providing both funding and support to help these companies develop disruptive solutions for unmet medical needs. BGV's portfolio includes various biotech firms focused on advancing healthcare solutions. Notable transactions include investments in argenx, which raised significant funding in Series A rounds in 2009 and 2010, indicating a strong interest in companies that are likely involved in biomedical advancements. Additionally, BGV invested in SurgVision, a company that raised funds in a venture round, further demonstrating their engagement in the biomedical engineering context. Their recent investment in Phosphoenix during a Pre-Seed round also highlights their ongoing commitment to supporting early-stage companies in the life sciences sector.


11. Thuja Capital

  • Website: thujacapital.com
  • Type: Venture Capital
  • Headquarters: Utrecht, Utrecht, Netherlands
  • Founded year: 2006
  • Headcount: 1-10
  • Number of deals in 2024: 3
  • LinkedIn: thuja-capital

Thuja Capital Management BV is a venture capital firm based in Utrecht, Netherlands, founded in 2006. The firm specializes in healthcare investments, focusing on supporting innovative healthcare ventures from start-up to scale-up. Thuja Capital provides funding and strategic guidance to companies in the biotech and medtech sectors, primarily targeting healthcare startups that are developing novel therapies and medical technologies. Notable transactions include their participation in funding rounds for ATRO Medical, which is working on clinical studies for medical devices, and Gradient Denervation Technologies, which is developing an ultrasound-based catheter device. These investments highlight Thuja Capital's commitment to advancing biomedical engineering innovations.


12. Pmv

  • Website: pmv.eu
  • Type: Venture Capital
  • Headquarters: Brussels, Brussels, Belgium
  • Founded year: 2001
  • Headcount: 51-200
  • Number of deals in 2024: 11
  • LinkedIn: pmv-eu

Participatiemaatschappij Vlaanderen (PMV) is a public entity that acts as an investment company for the Flemish government, founded in 2001. Based in Brussels, Belgium, PMV provides a range of financing solutions, including loans and co-financing, to startups, scale-ups, and established businesses across various sectors such as real estate, clean tech, and life sciences. PMV also offers consulting services to help businesses navigate investment challenges and achieve sustainable growth. In the biomedical engineering context, PMV has participated in significant funding rounds for companies like FEops, which raised €6M in Series B funding for its innovative heart intervention technologies, and Exact Imaging, which secured $21.5 million in Series C funding for its advanced imaging solutions. These investments highlight PMV's commitment to supporting advancements in biomedical engineering and life sciences.


13. NLC - The European Healthtech Venture Builder

  • Website: nlc.health
  • Type: Corporate
  • Headquarters: Amsterdam, North Holland, Netherlands
  • Founded year: 2014
  • Headcount: 51-200
  • Number of deals in 2024: 6
  • LinkedIn: nlc-next-level-challenge

NLC - The European Healthtech Venture Builder, founded in 2014 and based in Amsterdam, is a corporate investor focused on healthcare innovation and the development of medical technology solutions. They have a particular emphasis on neonatal care, as evidenced by their investment in Bilihome, which offers smart wearable light therapy for newborns suffering from jaundice. This innovation enhances the quality of care while allowing parents to maintain close contact with their infants. In 2024, NLC participated in a Series A funding round for MindAffect, a startup developing a combined hearing and vision test for young children and a glaucoma monitoring test for elderly patients, utilizing advanced brain-computer interface technology. Additionally, they have been involved in several pre-seed rounds, including investments in Haermonics, Venous Stent BV, and NC Biomatrix, all of which contribute to the biomedical engineering landscape. Their business model emphasizes collaboration with healthcare providers and investors to drive innovation in the sector, further solidifying their role as a key player in healthtech and biomedical engineering.


14. Exor N.V.

  • Website: exor.com
  • Type: Venture Capital
  • Headquarters: Amsterdam, North Holland, Netherlands
  • Founded year: 2009
  • Headcount: 11-50
  • Number of deals in 2024: 26
  • LinkedIn: exor_2

Exor N.V. is a holding company based in Amsterdam, Netherlands, founded in 2009. It operates across various sectors, including automotive, healthcare, and media, and manages a diverse portfolio of companies such as Ferrari, Stellantis, and Philips. Exor focuses on enhancing value through strategic investments and operational support. In the biomedical engineering context, Exor has made significant investments, including a €35 million investment in CorWave, a company developing innovative medical devices, and a $30 million investment in Allotex, which is working on technology for treating refractive errors. Additionally, Exor has invested in Sava, a medical device company specializing in wearable biosensor technology, demonstrating its commitment to advancing healthcare solutions. Furthermore, Exor acquired a 10% shareholding in Institut Mérieux, indicating its strategic interest in the healthcare sector.


15. Vesalius Biocapital Arkiv


Vesalius Biocapital Partners Sàrl is a venture capital firm based in Woluwe-Saint-Pierre, Brussels, Belgium, founded in 2007. The firm specializes in providing funding and strategic support to innovative life science companies across Europe, focusing on areas such as therapeutics, medical devices, and diagnostics. In 2024, Vesalius Biocapital has already made 8 investments, demonstrating their active role in the market. Notable transactions include a Series C financing round for Humedics GmbH, which raised over 6.3 million Euro to support the European market entry of their proprietary medical technology, LiMAx. Additionally, they participated in the Series C financing for Memo Therapeutics, which raised CHF 25 million to advance a Phase II trial for a therapeutic drug. These transactions highlight Vesalius Biocapital's commitment to supporting companies that are directly involved in biomedical engineering and related fields.


16. Cvc

  • Website: cvc.com
  • Type: Private Equity
  • Headquarters: Luxembourg
  • Founded year: 2005
  • Headcount: 1001-5000
  • Number of deals in 2024: 16
  • LinkedIn: cvc-capital-partners

CVC Capital Partners is a prominent investment firm founded in 2005, specializing in private equity, credit, secondaries, and infrastructure. With approximately €193 billion in assets under management for over 1000 clients, including pension funds and institutional investors, CVC focuses on delivering sustainable value and growth through strategic investments. In the biomedical engineering sector, CVC has made significant strides, including the acquisition of Spectrum Medical, a medical device company valued at up to £1 billion, and the acquisition of Therakos from Mallinckrodt for $925 million, which is expected to close in late 2024. Additionally, their acquisition of Rayner Surgical Group marks a strategic move towards global expansion in the medical field. These transactions underscore CVC's active role in the biomedical engineering landscape.



Biomedical Engineering Insights: Key Investors in Benelux


InvestorHeadquarterSizeFoundedDeals 2024
European Innovation Council (EIC)Brussels, Brussels, Belgium201-500195857
European Investment Bank (EIB)Luxembourg1001-5000195899
Life Sciences Partners (LSP)Amsterdam, North Holland, Netherlands11-50198715
ForbionNaarden, North Holland, Netherlands11-50200623
Gilde HealthcareUtrecht, Utrecht, Netherlands51-200198212
M VenturesAmsterdam, North Holland, Netherlands11-50200918
GimvAntwerp, Flanders, Belgium51-20019808
Brabantse Ontwikkelings Maatschappij (BOM)Tilburg, North Brabant, Netherlands51-200198310
NoshaqBelgium11-50198511
BGV (BioGeneration Ventures)Naarden, North Holland, Netherlands1-1020066
Thuja CapitalUtrecht, Utrecht, Netherlands1-1020063
PmvBrussels, Brussels, Belgium51-200200111
NLC - The European Healthtech Venture BuilderAmsterdam, North Holland, Netherlands51-20020146
Exor N.V.Amsterdam, North Holland, Netherlands11-50200926
Vesalius Biocapital ArkivWoluwe-Saint-Pierre, Brussels, Belgium1-1020078
CvcLuxembourg1001-5000200516


Want to find more investors focusing on the biomedical engineering industry?

If you want to find more investors that are active in the biomedical engineeringindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!